Top Tech Companies (28)
Don't see your company?
Create a company profile
Toronto-based infectious disease intelligence company, BlueDot, has developed a first-of-its-kind, global early warning technology for infectious diseases. Using artificial and human intelligence, BlueDot’s outbreak risk platform tracks over 120 infectious diseases globally in 65 languages, around the clock and anticipates their spread and impact. They empower national and international health agencies, pharma and life sciences companies, and businesses to better anticipate, and respond to, emerging threats. BlueDot was among the first in the world to identify the emerging risk from, and publish a scientific paper on, COVID-19, and delivers regular critical Insights to its partners and customers worldwide to mobilize timely, effective, efficient, coordinated, and measured responses. BlueDot was founded in 2013 by Dr. Kamran Khan, a practicing infectious disease physician, and Professor of Medicine with the Division of Infectious Diseases at the University of Toronto. Motivated by his experiences as a frontline healthcare worker during the 2003 Toronto SARS outbreak, Dr. Khan has been studying the outbreak of infectious diseases over the past 15 years to lay the scientific foundation for BlueDot’s early warning system.
MedAvail Inc. is the developer of the MedCenter automated dispensing and medication management technologies. The company designs and manufactures pharmacist-controlled automated prescription medicine dispensing vaults, similar in appearance to ATMs. Intended for deployment in hospitals, pharmacies, medical clinics, and other locations. The company integrates advanced robotics, two-way video teleconferencing, and a secure network for patients medical information to create a prescription medication dispensing system.
Reunion Neuroscience is committed to innovating therapeutic solutions to treat mental health conditions through the development of novel psychedelic compounds
Geneseeq is a research-driven company providing cutting-edge next-generation sequencing (NGS) technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type-specific gene panels for all sample types to help match a patient to the optimal treatment, including targeted therapy and immunotherapy for solid tumors and blood cancers. Additionally, we develop cutting-edge technologies and kits for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Our testing services are conducted in our CAP/CLIA/ISO15189-accredited laboratory, where we manufacture IVD and RUO testing kits for in-house solutions. With a global reach, our headquarters are located in both Canada and China. Our products and services are well-established and ordered by over 8,000 long-term oncologist partners across 12+ countries and regions. We are engaged in 2,200+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We work closely with our partners to address their specific needs, maintaining a relentless focus on quality and efficiency.
One trocar, three sizes, countless advantages
Insight Medbotics is developing MRI-guided robotics to bring together the insights only MRI can provide with the minimally invasive access and precision of robotics. Our MRI-compatible robot, IGAR, has been clinically demonstrated in breast cancer patients. IGAR can be used for biopsy, targeted therapy delivery, and device placement. Our vision is to bring our advanced MRI-guided robotic technology to procedures where accuracy and precision matter most to patients, physicians and hospitals.
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.
AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications. Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals. We have developed a platform technology which addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. Currently, we have developed a combination product for post-operative pain, which is our company's lead project.
